Elite Pharmaceuticals elects Aqeel A. Fatmi and John W. LaRocca to board
Займёт меньше минуты
Elite Pharmaceuticals elected Aqeel A. Fatmi and John W. LaRocca to its board, effective October 28, 2026.
| Individual | Aqeel A. Fatmi, Ph.D. | John W. LaRocca, Esq. |
| Role | Class II director | Class I director |
| Type of Change | Elected to the board | Elected to the board |
| Effective Date | October 28, 2026 | October 28, 2026 |
| Term | Until the next annual meeting of stockholders and until a successor is elected and qualified, or earlier death, resignation or removal | Until the next annual meeting of stockholders and until a successor is elected and qualified, or earlier death, resignation or removal |
| Reason | Not disclosed | Not disclosed |
| Board/Committee Role Changes | No committee assignment yet | No committee assignment yet |
| Compensation/Agreement Terms | Will receive compensation in the same manner as the board’s other non-management directors | Will receive compensation in the same manner as the board’s other non-management directors |
| Background Details | More than four decades in pharmaceuticals and biopharmaceuticals; has served as an independent strategic and technical advisor since 2016. | More than three decades of legal experience, including over two decades in pharmaceuticals; has held senior legal roles at several pharmaceutical companies. |
Original SEC Filing: ELITE PHARMACEUTICALS INC /NV/ [ ELTP ] - 8-K - Nov. 03, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.